Immune status of patients before initiation of chemotherapy
. | Case 1 results . | Case 2 results . |
---|---|---|
White blood cell count | 1.62 | 4.83 |
Lymphocyte count | 1.10 | 0.79 |
CD3+cells | ||
% | 28.8 | 70 |
Absolute count | 0.32 | 0.52 |
CD19+ cells | ||
% | 25.8 | 3 |
Absolute count | 0.28 | 0.02 |
CD16+CD56+cells | ||
% | 44.0 | 27 |
Absolute count | 0.48 | 0.20 |
CD3+CD4+cells | ||
% | 10.8 | 36 |
Absolute count | 0.12 | 0.27 |
CD3+CD8+cells | ||
% | 17.1 | 29 |
Absolute count | 0.19 | 0.21 |
CD4s; CD4+CD45RA+CD27+(naive) cells | ||
% | 27.9 | 9 |
Absolute count | 0.03 | 0.04 |
CD4s; CD4+CD45RA+ CD31+ (recent thymic emigrants), % | 20.3 | NA |
TRECs* | Negligible | 442 /106 T cells |
Spectratyping | 4 of 24 V-β families with a Gaussian distribution | 16 of 24 V-β families with a Gaussian distribution |
. | Case 1 results . | Case 2 results . |
---|---|---|
White blood cell count | 1.62 | 4.83 |
Lymphocyte count | 1.10 | 0.79 |
CD3+cells | ||
% | 28.8 | 70 |
Absolute count | 0.32 | 0.52 |
CD19+ cells | ||
% | 25.8 | 3 |
Absolute count | 0.28 | 0.02 |
CD16+CD56+cells | ||
% | 44.0 | 27 |
Absolute count | 0.48 | 0.20 |
CD3+CD4+cells | ||
% | 10.8 | 36 |
Absolute count | 0.12 | 0.27 |
CD3+CD8+cells | ||
% | 17.1 | 29 |
Absolute count | 0.19 | 0.21 |
CD4s; CD4+CD45RA+CD27+(naive) cells | ||
% | 27.9 | 9 |
Absolute count | 0.03 | 0.04 |
CD4s; CD4+CD45RA+ CD31+ (recent thymic emigrants), % | 20.3 | NA |
TRECs* | Negligible | 442 /106 T cells |
Spectratyping | 4 of 24 V-β families with a Gaussian distribution | 16 of 24 V-β families with a Gaussian distribution |
Cell counts are expressed as ×109/L.
The tenth percentile for TRECs in an age range of 6 to 12 years is 8534 TRECs/106 T cells.